IBM Joins Forces With the Some of World’s Top Cancer Centers to Accelerate Research, Diagnosis and Treatment

IBM Joins Forces With the Some of World’s Top Cancer Centers to Accelerate Research, Diagnosis and Treatment

IBM announced today it is joining forces with Memorial Sloan-Kettering Cancer Center (MSKCC), the Molecular Profiling Institute and the CHU Sainte-Justine Research Center – Mother and Child University Hospital Center under separate agreements to help accelerate cancer research, diagnosis and treatment. Recognizing the critical role that information technology (IT) will play in the 21st century in understanding and treating complex and deadly diseases like cancer, IBM is working with the people, technologies and partnerships needed to battle this deadly disease.

IBM and MSKCC are building a state-of-the-art integrated information management system to improve the ability of clinicians and researchers to study long-term cancer-related illnesses, identify disease trends and determine success rates. Funded by a $3 million grant of technology and services from IBM, MSKCC will include a comprehensive system to integrate its hospital data with text mining and related analytical capabilities into a unified information management environment to facilitate predictive analysis and research. In addition, pathologists at MSKCC are working closely with researchers at IBM to create a searchable database for pathology reports. IBM is also teaming with the Molecular Profiling Institute and the CHU Sainte-Justine Research Center – Mother and Child University Hospital Center under separate agreements to accelerate cancer research, diagnosis and treatment.

Read the complete Press Release